Compare FARM & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FARM | EVAX |
|---|---|---|
| Founded | 1912 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 27.4M |
| IPO Year | 1994 | 2020 |
| Metric | FARM | EVAX |
|---|---|---|
| Price | $1.54 | $3.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.75 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 77.5K | 44.1K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,281,000.00 | N/A |
| Revenue This Year | $4.36 | $128.77 |
| Revenue Next Year | $3.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.35 | N/A |
| 52 Week Low | $1.36 | $1.20 |
| 52 Week High | $3.28 | $12.15 |
| Indicator | FARM | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 41.85 |
| Support Level | $1.43 | $2.56 |
| Resistance Level | $1.61 | $3.54 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 24.62 | 35.00 |
Farmer Bros Co is engaged in manufacturing, wholesaling, and distributing coffee, tea, and culinary products to food-service establishments and retailers in the United States. The company's customers include restaurants, hotels, offices, casinos, convenience stores, healthcare facilities, and other food-service providers. The company's product categories include roast and ground coffee, frozen liquid coffee, flavored and unflavored iced and hot teas, culinary products, spices, and other beverages, such as cappuccino, cocoa, granitas, and ready-to-drink iced coffee.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.